NCT01142557View on ClinicalTrials.gov

An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

522

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon beta-1a (Rebif)

A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.

Trial Locations (1)

64289

Merck Serono GmbH, Darmstadt

All Listed Sponsors
collaborator

Gesellschaft für Therapieforschung mbH

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01142557 - An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis | Biotech Hunter | Biotech Hunter